[Endothelin and heart failure].
Miyauchi
Takashi
T
Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba.
D000818:Animals; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood / Q000235:genetics / Q000502:physiology*; D015870:Gene Expression; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009389:Neovascularization, Pathologic; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010666:Phenylpropionates / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014157:Transcription Factors / Q000502:physiology; D014661:Vasoconstriction; D020257:Ventricular Remodeling
D015415:Biomarkers; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D010456:Peptides, Cyclic; D010666:Phenylpropionates; D011743:Pyrimidines; D014157:Transcription Factors; C107831:darusentan; C072247:cyclo(Trp-Asp-Pro-Val-Leu)